Keyphrases
Breast Cancer Patients
100%
MicroRNA-21 (miR-21)
96%
Indonesia
82%
Surabaya
76%
Plasma miRNAs
72%
Breast Cancer
64%
Malignancy
48%
Hepatic Cirrhosis
48%
Anticoagulants
48%
Human Immunodeficiency Virus Type 1 (HIV-1)
48%
Rare Manifestation
48%
Cyclophosphamide
36%
Drug Resistance mutations
32%
COVID-19
31%
Drug-related Problems
31%
Sepsis
26%
21 Levels
24%
Bacillary Dysentery
24%
Smoldering multiple Myeloma
24%
Antihyperlipidemic
24%
Filgrastim
24%
Chemotherapy-induced Neutropenia
24%
TAC Chemotherapy
24%
Drug-naïve Individuals
24%
Plasmablastic Lymphoma
24%
Integrase
24%
Transmitted Drug Resistance mutations
24%
Lymphoma Cancer
24%
Multiple Malignancies
24%
6-cycles
24%
Screening Biomarker
24%
Carbohydrate Antigen 15-3
24%
Age-matched
24%
Breast Cancer Stage
24%
Plasma microRNA
24%
Associating Factors
24%
Antihypertensive Treatment
24%
Melena
24%
Hematemesis
24%
Antiretroviral Therapy
24%
Type 2 Diabetes Mellitus (T2DM)
24%
Absolute Neutrophil Count
24%
Thrombocytopenia
24%
Early Detection
24%
Referral Hospital
24%
Transfusion-dependent Thalassemia
24%
Diagnostic Challenge
24%
High-sensitivity C-reactive Protein (hs-CRP)
24%
Anatomical Pathology
24%
Intracranial Hemorrhage
24%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
72%
Anticoagulant Agent
50%
Liver Cirrhosis
48%
Drug Resistance
48%
microRNA 21
48%
Human Immunodeficiency Virus 1
48%
Chemotherapy
48%
C Reactive Protein
38%
Diseases
30%
Retrospective Study
30%
Cross-Sectional Study
29%
Ferritin
29%
Thrombosis
29%
Sepsis
26%
Antihypertensive Agent
24%
Melena
24%
Docetaxel
24%
Neutropenia
24%
Filgrastim
24%
Disease Exacerbation
24%
Integrase
24%
Thrombocytopenia
24%
Parathyroid Hormone
24%
Chronic Kidney Failure
24%
Coronavirinae
24%
Ascites
24%
Thalassemia
24%
Hematemesis
24%
Cyclophosphamide
24%
Proton Pump Inhibitor
24%
Biological Marker
24%
Survival Rate
24%
Dyslipidemia
24%
Non Insulin Dependent Diabetes Mellitus
24%
Diuretics
24%
Collagen Type 1
24%
Imatinib
24%
Chronic Myeloid Leukemia
24%
Telopeptide
24%
Osteocalcin
24%
Gemcitabine
24%
Deep Vein Thrombosis
24%
Adenocarcinoma
24%
Capecitabine
24%
Malignant Neoplasm
19%
D Dimer
19%
Antihypertensive Therapy
18%
Integrase Inhibitor
18%
Cancer Staging
16%
Febrile Neutropenia
10%
Medicine and Dentistry
Cancer
72%
COVID-19
60%
C Reactive Protein
38%
Anticoagulant
33%
Case Presentation
32%
Antithrombotic
31%
Cross Sectional Study
29%
Ferritin
29%
Sepsis
24%
Smouldering Myeloma
24%
Thrombocytopenia
24%
Plasmablastic Lymphoma
24%
Plasmacytoma
24%
Pericardial Fluid
24%
Lung Cancer
24%
Diagnosis
24%
Anatomical Pathology
24%
Hormone Determination
24%
Breast Cancer
24%
Cerebral Hemorrhage
24%
Proton-Pump Inhibitor
24%
Retrospective Study
24%
Dysentery
24%
Patient Referral
24%
Hormone Therapy
24%
Evans Syndrome
24%
Thalassemia
24%
Liver Cirrhosis
24%
Disease Exacerbation
24%
Parathyroid Hormone
24%
Hematemesis
24%
Melena
24%
Patient with Non-Hodgkins Lymphoma
24%
Tamponade
24%
Neutrophil
24%
C-Terminal Telopeptide
24%
Capecitabine
24%
D-Dimer
19%
Lymphocyte
19%
Cheek
16%
Ductal Carcinoma
12%
Epirubicin
12%
Computer Assisted Tomography
12%
Overall Survival
12%
B Cell
12%
Vincristine
12%
Primary Tumor
12%
Prednisone
12%
Rituximab
12%
Cyclophosphamide
12%